Markets
Hims & Hers website.
Hims & Hers website

Hims & Hers investors run for the hills despite earnings beat and cheery outlook

Hims & Hers outlook and earnings weren’t enough to quell investors’ fears.

J. Edward Moreno

Hims & Hers Health, the tele-pharmacy known for selling copycat versions of popular weight-loss drugs, tanked in aftermarket trading despite largely meeting Wall Street expectations and giving upbeat guidance.

The company reported earnings per share of $0.12, edging above the $0.11 analysts polled by FactSet were expecting. It also reported $481.1 million in revenue, compared to the $470.3 million analysts expected.

Hims & Hers said it expected revenue for the first quarter of 2025 to be between $520 million and $540 million, compared to the $497 million analysts had penciled in. This was the fifth straight quarter that Hims & Hers turned a profit, and 2024 marked its full profitable year.

Still, investors sent the company’s stock down more than 15% in after-hours trading.

Investors are likely still spooked by the news that the Food and Drug Administration declared that semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, is no longer in a shortage, limiting Hims & Hers’ ability to make copycat versions.

Removing it from the shortage list means Hims & Hers can no longer sell exact copies of the drug; it’s only allowed to if it adjusts the drug. Hims & Hers CEO Andrew Dudum said in a Friday statement that the company plans to continue selling compounded semaglutide in the form of “personalized treatments.”

Hims & Hers said in its letter to shareholders that it can sell “personalized titration schedules and dosage levels that are not essentially copies of commercially available medications” even with a shortage in place.

But in a footnote repeated three times in the letter, the company said the FDA move “could constrain our ability to continue providing access to compounded semaglutide on our platform once our current inventory has been sold.”

The company did not explicitly report how much it made selling weight-loss drugs, which it started doing in May 2024. It did say that revenue from non-GLP-1 drugs was $1.2 billion of the $1.4 billion it brought in 2024, suggesting it sold roughly $200 million in copycat weight-loss drugs last year.

More Markets

See all Markets
Tasha Matsumoto
3h
Tech drags down stocks; gold and silver plummet

Gold and silver sank amid Trump’s plans to nominate reputed inflation hawk Kevin Warsh as the next Fed chair.

Public sculptures along the Clear Creek Trail in downtown Golden, Colorado.
Ben Walsh, Luke Kawa

Gold and silver plunge, suffering their worst losses since the 1980s

Gold and silver suffered their worst losses in decades on Friday, with the iShares Silver Trust falling more than 30% at one point during afternoon trading before recovering slightly.

After recently crossing $5,000 per ounce for the first time, gold’s dip was relatively muted compared to silver’s rout, but nevertheless eye-watering for a traditional safe haven asset. At one point, gold’s intraday dip exceeded 10%, its worst intraday drop since the 1980s and surpassing its declines seen during the 2008 financial crisis, per Bloomberg.

Silver’s drop was its worst in percentage terms since 1980.

Gold, and particularly silver, have been pushed higher recently by a storm of retail trader enthusiasm for the metals, as well as more traditional drivers of precious metals such as geopolitical risks and concerns over a fall in the dollar’s value due to trade wars and possibly waning central bank independence.

Leveraged ETFs that hold gold and silver futures have become increasingly popular trading vehicles amid the parabolic moves in precious metals prices, and likely contributed to the magnitude of the unwind today.

Case in point: look at silver futures for delivery in March. That’s the dominant contract held by the ProShares Ultra Silver ETF, which offers exposure to 2x the daily move in the shiny metal. Volumes exploded (and the contract rebounded modestly) right around 1:25 p.m. ET, which is when silver futures settled and around the time the ETF performed its daily rebalancing (which in this case, involved massive selling).

Max Knoblauch

Gaming stocks plunge following release of Google’s AI tool that can create playable, copyrighted worlds

Shares of major gaming companies are plunging on Friday as investors get a deeper look at the capabilities of Google’s new generative-AI prototype, Project Genie.

The tool allows users to “create and explore infinitely diverse worlds” with a text or image prompt. Users have already exposed its ability to realistically recreate knockoffs of copyrighted games from Nintendo and other gaming companies.

As users experiment with recreations of game worlds like Take-Two’s “Grand Theft Auto 6,” shares of major gaming companies are sinking. Unity Software, the maker of the popular Unity game engine, is down over 25%, while gaming platform Roblox is down about 9%.

Collision 2019 - Day One

D-Wave Quantum CEO on what’s next after the most eventful month in the company’s history

“If 2025 was the international year of quantum, 2026 is the international year of D-Wave Quantum,” said CEO Dr. Alan Baratz.

Luke Kawa9h
markets
Matt Phillips

SoFi bests Wall Street’s Q4 expectations, shares rise

SoFi Technologies reported better-than-expected Q4 sales and earnings-per-share numbers Friday before market open, sending the shares higher in the premarket. 

The online lender reported: 

  • Adjusted Q4 earnings per share of $0.13 vs. the $0.12 consensus estimate collected by FactSet.

  • Adjusted revenue of $1.01 billion in Q4 vs. the Wall Street forecast for $977.4 million.

  • Q1 2026 adjusted net revenue guidance of approximately $1.04 billion vs. the $1.04 billion consensus expectation, according to FactSet.

SoFi shares rallied roughly 70% last year, as the company’s growing menu of financial products — including trading, wealth management, mortgages, credit cards, and cryptocurrency trading — showed signs of gaining traction beyond its traditional base of student borrowers. But the stock has stumbled in early 2026, falling nearly 7% in January through Thursday’s close, though most of that slump seems to have been reversed this morning.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC